Defeat Diabetes: Lidocaine Patch Provides Effective Analgesia for Painful
Diabetic Neuropathy
Lidocaine Patch Provides Effective Analgesia for
Painful Diabetic Neuropathy
posted 12/18/02
A transdermal patch,
Lidoderm (lidocaine
5 percent) appears to provide significant improvement in both pain intensity
and pain relief for patients with painful diabetic neuropathy.
That, from the researchers at
the clinical meeting of the American Society of Health-System Pharmacists on
December 10th
The results are important, researchers said, because the condition affects more
than 50 percent of elderly patients with diabetes and is notoriously difficult
to treat effectively.
The lidocaine patch is a targeted peripheral analgesic that has proved effective
in treating postherpetic neuralgia. As such, it may be a potentially powerful
strategy for treating painful diabetic neuropathy, according to the researchers,
led by Stephanie Hart-Gouleau, MD, of the department of anaesthesiology at the
University of Rochester School of Medicine, in Rochester, New York, United
States.
The multi-centre, three-week, open-label, prospective trial included 56 men and
four women aged 18 to 90 years with painful diabetic neuropathy of at least
three months' duration and average daily pain ratings of 4 or higher on numeric
pain scale.
Patients were treated with up to four lidocaine patches daily applied to areas
of maximal peripheral neuropathic pain, in an 18-hours-on, six-hours-off manner.
They were permitted to continue their analgesic medication regimen throughout
the trial, as long as dosing remained stable.
For the 51 patients who completed the three weeks of treatment, the lidocaine
patch provided significant reductions in pain. At baseline, mean overall pain
relief from current therapy was 28.8 percent, compared to a mean of 63.1 percent
at the end of the three weeks.
The results are encouraging, the researchers said, because the patch provided
analgesia without local anaesthesia, and there were no serious treatment-related
systemic adverse events or drug-to-drug interactions. The most frequently
reported adverse event, which affected seven patients, was application site
burning.
The researchers said that in light of the promising nature of the results,
additional controlled clinical trials should be undertaken to further
characterise the efficacy of the lidocaine patch in treating painful diabetic
neuropathy.
Source: Diabetes In Control Dot Com.
December
News Article Index
Home -
Table of
Contents -
Donate Now -
About
Diabetes -
Warning Signs -
Complications
- Screening Test -
Diabetes
Terms -
Site Search -
Meet
Mr. Diabetes® -
Wake Up And
Walk® Tour -
Latest News -
Headlines
& News Stories -
Health
& Fitness -
About Us -
FAQ
- Research Form -
-
Message Board -
Privacy
Policy -
Legal Notices
-
How to Contact Us
-
Comments form -
Suggestion Form
- Our E-Mail
Addresses -
Our Address and Phone
Numbers -
Links
-
Contact Us